Stephen P. Hunger mostly deals with Internal medicine, Cancer research, Oncology, Acute lymphocytic leukemia and Childhood Acute Lymphoblastic Leukemia. His Cancer research research incorporates themes from Genetics, Leukemia, Mutation, Tyrosine kinase and Philadelphia chromosome. His work carried out in the field of Philadelphia chromosome brings together such families of science as Janus kinase 2, ABL and PDGFRB.
His work deals with themes such as Cancer, Clinical trial, Methotrexate, Young adult and Multivariate analysis, which intersect with Oncology. His Acute lymphocytic leukemia research is multidisciplinary, incorporating elements of Exon, Cell cycle, Gene expression profiling and Chromosomal translocation. The study incorporates disciplines such as Mercaptopurine, Survival rate, Case-control study, Single-nucleotide polymorphism and Acute leukemia in addition to Childhood Acute Lymphoblastic Leukemia.
His primary scientific interests are in Internal medicine, Oncology, Cancer research, Leukemia and Acute lymphocytic leukemia. His work in the fields of Minimal residual disease, Chemotherapy, Lymphoblastic Leukemia and Cohort overlaps with other areas such as Cog. His Oncology research is multidisciplinary, relying on both Cancer, Clinical trial, Methotrexate, Childhood Acute Lymphoblastic Leukemia and Prednisone.
In his study, which falls under the umbrella issue of Cancer research, Dasatinib and PDGFRB is strongly linked to ABL. The Leukemia portion of his research involves studies in Immunology and Genetics. His studies deal with areas such as Regimen, Gene expression profiling and Chromosomal translocation as well as Acute lymphocytic leukemia.
His scientific interests lie mostly in Internal medicine, Oncology, Leukemia, Cancer research and Lymphoblastic Leukemia. His work in the fields of Internal medicine, such as Chemotherapy, Minimal residual disease, Clinical trial and Cancer, overlaps with other areas such as Cog. His Oncology research incorporates elements of Hematopoietic stem cell transplantation, Methotrexate, Young adult, Randomized controlled trial and Group study.
His Cancer research research includes themes of T cell, Transcription factor and Cell culture. His Lymphoblastic Leukemia research is multidisciplinary, incorporating perspectives in Treatment outcome, Down syndrome and Pediatrics. In Acute lymphocytic leukemia, Stephen P. Hunger works on issues like Childhood Acute Lymphoblastic Leukemia, which are connected to Genotype and Genome-wide association study.
Stephen P. Hunger mainly focuses on Internal medicine, Oncology, Chemotherapy, Cancer research and Lymphoblastic Leukemia. Internal medicine is closely attributed to Gastroenterology in his work. His research in Oncology intersects with topics in Clinical trial, Young adult, Randomized controlled trial, Philadelphia chromosome and Leukemia.
His studies in Chemotherapy integrate themes in fields like Proteasome inhibitor, Proteasome Inhibition and Bone marrow, Minimal residual disease. The Cancer research study combines topics in areas such as Cell growth, Phenotype, T cell, Apoptosis and Transcription factor. When carried out as part of a general Lymphoblastic Leukemia research project, his work on Asparaginase is frequently linked to work in Extramural and Text mining, therefore connecting diverse disciplines of study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Jinghui Zhang;Li Ding;Linda Holmfeldt;Gang Wu.
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
Charles G Mullighan;Xiaoping Su;Jinghui Zhang;Ina Radtke.
The New England Journal of Medicine (2009)
Acute Lymphoblastic Leukemia in Children
Stephen P. Hunger;Charles G. Mullighan.
The New England Journal of Medicine (2015)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts;Y. Li;D. Payne-Turner;R. C. Harvey.
The New England Journal of Medicine (2014)
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
Stephen P. Hunger;Xiaomin Lu;Meenakshi Devidas;Bruce M. Camitta.
Journal of Clinical Oncology (2012)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Michael J. Borowitz;Meenakshi Devidas;Stephen P. Hunger;W. Paul Bowman;W. Paul Bowman.
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
Kirk R. Schultz;W. Paul Bowman;Alexander Aledo;William B. Slayton.
Journal of Clinical Oncology (2009)
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst.
Cancer Cell (2012)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching Hon Pui;Jun J. Yang;Stephen P. Hunger;Rob Pieters.
Journal of Clinical Oncology (2015)
JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Charles G. Mullighan;Jinghui Zhang;Richard C. Harvey;J. Racquel Collins-Underwood.
Proceedings of the National Academy of Sciences of the United States of America (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: